Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC)

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3275-3278

  Noroxe, Dorte Schou ^a   Wallerek, Sandra ^a   Sorensen, Jens Benn ^a  

^a Finsen Centre National University Hospital   (Denmark)

Author keywords

Angiogenesis; Bevacizumab; Brain metastases; Humanized monoclonal antibody; Lung cancer; Non small cell lung cancer; NSCLC; Overall survival; Platinum based chemotherapy; Progression free survival; Pulmonary haemorhage; Vascular endothelial growth factor A (VEGF A)

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; NAVELBINE; PLATINUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VAGINA BLEEDING;

ANGIOGENESIS; BEVACIZUMAB; BRAIN METASTASES; HUMANIZED MONOCLONAL ANTIBODY; LUNG CANCER; NON-SMALL CELL LUNG CANCER; NSCLC; OVERALL SURVIVAL; PLATINUM-BASED CHEMOTHERAPY; PROGRESSION-FREE SURVIVAL; PULMONARY HAEMORHAGE; VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A);

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; VINBLASTINE;

EID: 84883303017     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. http://www.lungecancer.dk/documents/08D91DE2-CD7A-49AE-9DE9-7F5DB8D1AD05. pdf (last assesed 28.06.13).
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
3. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 27: 1227-1234, 2009.
4. Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J and Johnson DH: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevazicumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5: 1416-1423, 2010.
5. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Overall survival with cisplatin-gemcitabine and bevazicumab or placebo as first-line therapy for nonsquamous non-small cell lung cancer: Results from a randomized phase III trail (AVAiL). Ann Oncol 21: 1804-1809, 2010.
6. Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M and Kohlhaeufl M: MO 19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer 76: 373-379, 2012.
7. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher D, Tsai CM, Wu YL and Zhou C: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SaiL, MO19390): A phase IV study. Lancet Oncol 11: 733-740, 2010.
8. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E and Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Onc 22: 2184-2191, 2004.
9. Reck M, Barlesi F, Crino L et al: Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23: 1111-1120, 2012.
10. Wozniak AJ, Garst J, Jahanzeb M, Kosty MP, Vidaver R, Beatty S, Teng S, Flick ED, Sing A and Lynch TJ: Clinical outcomes (CO) for special populations of patients (pts) with advanced nonsmall- cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Clin Oncol 28: 15s, 2010.
11. Besse B, Lasserre SF, Compton P, Huang J, Augustus S and Rohr UP: Bevacizumab safety in patients with central nervous metastases. Clin Canc Res 16: 269-278, 2010.
12. NCCN Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, v2.2010. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
13. AvastinR(bevacizumab). Summary of Product Characteristics; 2009, available at http://www.emea.europa.eu/ema/index.jsp? curl=pages/medicines/ human/medicines/000582/human-med-00 0663.jsp&mid=WC0b01ac058001d124 (last assesed 26.06.13).
14. Botrel TEA, Clark O, Clark L, Paladini L, Faleiros E and Pegoretti B: Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small-cell lung cancer (NSCLC): Systematic review and meta-analysis. Lung Cancer 74: 89-97, 2011.